A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
NCT ID: NCT06637371
Last Updated: 2025-11-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
124 participants
INTERVENTIONAL
2024-10-16
2027-06-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part A: Single Ascending Dose (SAD)
Healthy participants will be randomized in a 3:1 ratio to receive either AMG 691 or placebo.
AMG 691
Subcutaneous (SC) injection
Placebo
SC injection
Part B: Multiple Ascending Dose (MAD)
Healthy participants will be randomized in a 3:1 ratio to receive either AMG 691 or placebo.
AMG 691
Subcutaneous (SC) injection
Placebo
SC injection
Part C: Multiple Dose
Participants with mild-to-moderate asthma will be randomized in a 2:1 ratio to receive either AMG 691 or placebo.
AMG 691
Subcutaneous (SC) injection
Placebo
SC injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AMG 691
Subcutaneous (SC) injection
Placebo
SC injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants must be 18 to 65 inclusive at time of signing of informed consent.
* Participants must have a Body Mass Index between 18.0 to 30 kg/m2 and total body weight ≥ 40 kg at screening.
* Participants must be overtly healthy as determined by the investigator based on medical evaluation and study screening procedures.
* Female participants must be of non-childbearing potential.
Inclusion Part C
* Participants must be capable of giving informed consent and have provided informed consent.
* Participants must be 18 to 65 inclusive at time of signing of informed consent.
* Participants must have documentation of physician diagnosed asthma for ≥ 12 months prior to screening.
* Participants must have documented bronchodilator responsiveness of forced expiratory volume in 1 second (FEV1) ≥ 12% and ≥200 mL in the 10 years before screening or at the screening visit.
* Participants must have a pre-bronchodilator percent predicted FEV1 between 50 and 100% inclusive at screening visit and Day -1.
* Participants must have peripheral blood eosinophils ≥ 200 cells/μl at screening visit and Day -1
* Participants must have a fractional exhaled nitric oxide (FeNO) ≥ 25 ppb at screening visit and Day -1.
* Participant must not use inhaled corticosteroids (ICS) or must be treated with low-dose or medium-dose ICS and on a stable dose for a minimum of 12 weeks prior to screening.
Exclusion (applicable to all study parts)
* History of malignancy (except for in situ cervical cancer or surgically excised non-melanoma skin cancer occurring more than 5 years prior to randomization).
* History of anaphylaxis or hypersensitivity to biologic therapy or sensitivity to mammalian derived products.
* History of immunodeficiency or history of severe infection within the last 3 years requiring IV antibiotics.
* History of tuberculosis (TB), TB symptoms, or positive interferon gamma release assay.
* History of untreated or unresolved helminthic infection within 24 weeks of day 1.
* Positive human immunodeficiency virus (HIV) antibodies, hepatitis B core antigen, hepatitis B core antibody, or hepatitis C virus (HCV) ribonucleic acid (RNA).
* Male participants unwilling to follow contraceptive requirements.
Additional Exclusion for Part C only
* Female of childbearing potential not willing to use 2 methods of contraception with one being a highly effective method of contraception.
* History of pulmonary disease that may interfere with interpretation of study results.
* History of upper respiratory infection within 6 weeks of screening.
* Asthma Control Questionnaire (ACQ-6) \> 3
* Asthma symptoms or exacerbations requiring 2 or more systemic corticosteroid bursts (≥10 mg/day prednisone or equivalent for ≥ 3 days each) in the previous 12 months.
* More than one hospitalization or emergency department visit in the last year.
* History of life-threatening asthma exacerbation requiring admission to intensive care unit.
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amgen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MD
Role: STUDY_DIRECTOR
Amgen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Orange County Research Center
Lake Forest, California, United States
Translational Clinical Research LLC
Aventura, Florida, United States
Destiny Research Center
Palmetto Bay, Florida, United States
ClinCept, LLC
Columbus, Georgia, United States
Brigham and Womens Hospital
Boston, Massachusetts, United States
Mayo Clinic
Rochester, Minnesota, United States
Prism Research LLC dba Nucleus Network
Saint Paul, Minnesota, United States
University of North Carolina Clinical and Translational Research Center
Chapel Hill, North Carolina, United States
North Carolina Clinical Research
Raleigh, North Carolina, United States
Endeavor Clinical Trials
San Antonio, Texas, United States
Clinical Medical and Analytical eXellence CMAX
Adelaide, South Australia, Australia
Algemeen Ziekenhuis Sint Maarten-Emmaus vzw
Mechelen, , Belgium
Winchester District Memorial Hospital
Winchester, Ontario, Canada
VPD Heart and Lung Research Institute
Cambridge, , United Kingdom
Chelsea and Westminster Hospital
London, , United Kingdom
The Medicines Evaluation Unit
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Related Links
Access external resources that provide additional context or updates about the study.
AmgenTrials clinical trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20230151
Identifier Type: -
Identifier Source: org_study_id